Brought to you by 
Pfizer develops Eyetech's Macugen
09 May 2007
Executive Summary
Pfizer and Eyetech Pharmaceuticals (develops drugs to reduce and prevent vision loss caused by eye disease) will jointly develop and commercialize Eyetech's Macugen (pegaptanib sodium) for treating age-related macular degeneration (AMD) and diabetic macular edema (DME).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com